DEBORAH DANIELS: Open Payments
NPI 1962956268 · CORBIN, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$443 in 32 payments from 10 companies in 2025. Trend: 2023 $350 · 2024 $192 · 2025 $443
Food & beverage: $443
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $187 |
| Vanda Pharmaceuticals Inc. | 2 | $56 |
| Alkermes, Inc. | 3 | $46 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Braeburn Inc. | 1 | $15 |
| Indivior Inc. | 1 | $14 |
Products named: QULIPTA, MAVYRET, VRAYLAR, LYBALVI, REXULTI, CAPLYTA, HETLIOZ, FANAPT.
Industry payments across KY — which companies pay providers there.
